HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 28, 26612-26621, July 15, 2005

This Article Abstract Full Text (PDF) All Versions of this Article: 280/28/26612    most recent M501359200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hinkovska-Galcheva, V. Articles by Shayman, J. A. Search for Related Content PubMed PubMed Citation Articles by Hinkovska-Galcheva, V. Articles by Shayman, J. A. Social Bookmarking                      What's this?

Ceramide 1-Phosphate, a Mediator of Phagocytosis^*

Vania Hinkovska-Galcheva, Laurence A. Boxer, Andrei Kindzelskii, Miki Hiraoka¶, Akira Abe¶, Sravan Goparju||, Sarah Spiegel||, Howard R. Petty**, and James A. Shayman¶

From the Department of Pediatrics, Division of Hematology/Oncology, Department of Ophthalmology and Visual Science, ^¶Department of Internal Medicine, Division of Nephrology, and ^||Department of Biochemistry, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298 and ^**Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109

Received for publication, February 4, 2005 , and in revised form, May 13, 2005.

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
The agonist-stimulated metabolism of membrane lipids produces potent second messengers that regulate phagocytosis. We studied whether human ceramide kinase (hCERK) activity and ceramide 1-phosphate formation could lead to enhanced phagocytosis through a mechanism involving modulation of the membrane-structural order parameter. hCERK was stably transfected into COS-1 cells that were stably transfected with the FcRIIA receptor. hCERK-transfected cells displayed a significant increase in phagocytic index in association with increased ceramide kinase activation and translocation to lipid rafts after activation with opsonized erythrocytes. When challenged with opsonized erythrocytes, hCERK-transfected cells increased phagocytosis by 1.5-fold compared with vector control and simultaneously increased ceramide 1-phosphate levels 2-fold compared with vector and unstimulated control cells. Control and hCERK-transfected cells were subjected to cellular fractionation. Utilizing an antibody against hCERK, we observed that CERK translocates during activation from the cytosol to a lipid raft fraction. The plasma membrane-structural order parameter of the transfectants was measured by labeling cells with Laurdan. Cells transfected with hCERK showed a higher liquid crystalline order than control cells with stimulation, conditions that are favorable for the promotion of membrane fusion at the sites of phagocytosis. The change in the structural order parameter of the lipid rafts probably contributes to phagocytosis by promoting phagosome formation.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
The second messengers produced by membrane lipids through agonist stimulation include not only glycerolipids but also sphingolipids. Sphingolipids are comprised of lipids that contain a long chain sphingoid base. Sphingolipids, in addition to being structural components of membranes, regulate cell-cell and cell-substrate interactions, proliferation, and differentiation. Members of this diverse group of lipids have emerged as a novel class of signaling molecules that also regulate phagocytosis. The mechanisms by which sphingolipids exert these effects remain incompletely defined. More than a decade ago, it was found that ceramide can be phosphorylated to ceramide 1-phosphate (C1P)¹ (1-3).

C1P is found in brain synaptic vesicles, and it is thought to play a role in regulating the secretion of neurotransmitters by promoting the fusion of vesicle membranes (4). Ceramide kinase activity exists in HL-60 cells where C1P is derived from ceramide released from sphingomyelin (5). Human ceramide kinase (hCERK) was recently cloned based on the homology to two isoforms of mice and human sphingosine kinase (6). The expressed kinase displayed specific ceramide phosphorylating activity. BLAST search analyses using the hCERK sequence revealed that a series of putative CERKs exist in a variety of cellular organisms, including plants, nematodes, insects, and vertebrates. CERKs represent a new class of lipid kinases that are clearly distinct from sphingosine and diacylglycerol kinases (6, 7).

C1P shares structural homology with phosphatidic acid, a lipid shown to be highly fusogenic (8). In an earlier study, the generation of C1P was also observed to occur through the activation of a ceramide kinase in polymorphonuclear leukocytes (7). In this model, C1P was found to be a potent fusogen. The addition of C1P to liposomes shifted the rate and extent of calcium-dependent fusion (7). Thus C1P was postulated to play a role in phagosome formation. Subsequently, it was reported that the CERK mediates Ca²⁺-dependent degranulation in mast cells (9). Others have also found that A549 cells transfected with the hCERK can induce arachidonate release and prostanoid synthesis (10).

Neutrophils are difficult to maintain in vitro for prolonged periods of time and are not amenable to transfection. Therefore, other model systems are often employed to probe the mechanism of phagocytosis and phagosome formation. COS-1 cells are one such model system. COS-1 cells acquire a phagocytic phenotype when transfected with the FcRIIA receptor. In the present study, we evaluated the effects of transfecting COS-1 cells expressing FcRIIA with the cDNA for hCERK on phagocytosis. Using the fluorescent probe Laurdan, we employed high-speed microspectrophotometry to examine the mechanism by which C1P enhances phagocytosis. We found that C1P increased during phagocytosis and that a distinct gel-like order lipid phase (Lo) was formed within the cell membrane at sites of C1P formation in the hCERK-transfected cells.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Materials—All of the phospholipids, imidazole, diethylenetriaminepentaacetic acid, n-octyl--D-glucopyranoside, and proteinase inhibitors pepstatin and leupeptin and monoclonal anti-c-Myc antibody were obtained from Sigma. Dithiothreitol was purchased from Calbiochem. Silica Gel 60 thin layer chromatography plates were purchased from VWR (Chicago, IL). [-³²P]ATP was obtained from ICN Pharmaceuticals, Inc. (Irvine, CA). Western blotting detection reagents and horseradish peroxidase-conjugated sheep anti-mouse antibody were from Amersham Biosciences. D-Erythro-[³H]sphingosine (2 mCi/ml) was purchased from American Radiolabeled Chemical Inc. (St. Louis, MO). Goat-anti-rabbit IgG-horseradish peroxidase was from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal antibody against caveolin-1 protein was purchased from Chemicon Int. (Temecula, CA). Dulbecco's modified Eagle's, medium, Opti-MEM medium, trypsin EDTA, L-glutamine, penicillin/streptomycin, and Geneticin (G-418 sulfate) were from Invitrogen. Zeocin and Lipofectamine reagent were from Invitrogen. Sheep erythrocytes were purchased from BioWhittaker (Walkersville, MD) and were opsonized with anti-sheep erythrocyte IgG from Chapel Organon Teknika (Durham, NC). Polyvinylidene difluoride membranes were from Schleicher & Schuell.

Cell Culture—COS-1 cells, stably transfected with FcRIIA receptor cDNA, were maintained in Dulbecco's modified Eagle's medium containing 4.5 mg/ml glucose, 25 mg/ml glutamine, 100 units/ml streptomycin, 100 mg/ml penicillin, and 10% heat-inactivated fetal calf serum (11). To create double expression transfectants with FcRIIA and hCERK, COS-1 cells transfected stably with FcRIIA were cultured in 35-mm dishes. At 80% confluence, the cells were transfected with 1 µg/ml pcDNA-hCERK expression vector using Lipofectamine Plus in 1 ml of Opti-MEM medium. 1 ml of Dulbecco's modified Eagle's medium containing 20% fetal bovine serum was added after 3 h of incubation at 37 °C, 5% CO₂. To establish stable transfectants, cells were cultured with medium containing 200 µg/ml G-418 and 200 µg/ml Zeocin to select double transfectants.

Sheep Erythrocytes—Sheep red blood cells were sensitized with rabbit IgG anti-sheep erythrocyte antibody as previously described (12). Phagocytosis assays were conducted as previously described (13).

hCERK Expression Vector—A plasmid carrying the hCERK gene was kindly provided by Dr. Takafumi Kohama (Sankyo Co, Ltd.). PCR amplifications were employed for 35 cycles with steps at 94 °C for 1 min, 60 °C for 1 min, and 72 °C for 1.5 min with Platinum Pfx DNA polymerase (Invitrogen) and CERK plasmid as templates. Primers used for PCR included hCERK-HindIII (5'-TTATATTTATCCCAAGCTTGGGATGGGGGCGACGGGGGCGGCGGA-3') and hCERK-XhoI (5'-ATACCGCTCGAGCGGTGACTCTTCCTCCTCGATTCCCCGAGCAAA-3'). PCR products were ligated into the pCR4-TOPO vector (Invitrogen) followed by cloning, purification of plasmids, and sequencing. The entire open reading frame of the hCERK was excised at HindIII and XhoI sites from the plasmid described above. The open reading frame was then subcloned into the HindIII and XhoI sites of a pcDNA3.1/Zeo(+) (Invitrogen) vector, which was modified to encode a C-terminal c-Myc tag to express a c-Myc-hCERK fusion protein.

Construction of Catalytically Inactive hCERK—A search of the hCERK amino acid sequence for signaling domains using the SMART search tool revealed a similarity in residues 132-278 of hCERK to the putative diacylglycerol kinase (DGK) catalytic domain. One region of the hCERK sequence showing highest similarity corresponded to the proposed ATP-binding site of the DGK catalytic domain. This region in DGK displays some resemblance to the glycine-rich loop within the ATP-binding site of many protein kinases but is more divergent in hCERK. The glycine residue in this region is known to be essential for DGK catalytic activity, because mutation of this residue to aspartate ablates activity in all of the DGK family members examined, including the DGK region of sphingosine kinase. Therefore, in an attempt to produce a catalytically inactive hCERK, the corresponding glycine (Gly¹⁹⁸) was mutated to aspartate in hCERK. A mutation was introduced in Myc-tagged hCERK in the pcDNA3 expression vector via mutagenic oligonucleotides using primers G198D-F (forward, 5'-CGGAGATGATATGTTCAGCGAG-3') and G198D-R (reverse, 5'-GCTGAACATATCATCTCCGCCGAC-3') by overlap extension methodology.

Ceramide Kinase Activity Assay—Ceramide kinase activity was measured as described by Bajjaleih et al. (1). Sonicated cells were incubated for 10 min at 30 °C in a reaction mixture containing 5 µM ceramide (solubilized in 7.5% octyl--D-glucopyranoside, 5 mM cardiolipin in 1 mM diethylenetraminepentaacetic acid), 50 mM HEPES, pH 6.8, 100 mM KCl, 1 mM EGTA, 10 µM [-³²P]ATP (4 Ci/mmol), and 3 mM CaCl₂. The reaction was terminated with 4 ml of chloroform/methanol (1:1) and 1 ml of 1 mM NaCl. An equal volume of the chloroform phase was removed and dried under nitrogen. Lipids were resolved by high performance thin layer chromatography on Silica Gel G60 with chloroform/acetone/methanol/acetic acid/water (40/16/12/8/4, v/v) solvent system. The products were visualized by autoradiography and quantified by liquid scintillation counting.

Radiolabeling of COS-1 Cells—In order to measure C1P, COS-1 cells transfected with hCERK were labeled with D-erythro-[³H]sphingosine. Stably transfected COS-1 cells were labeled with D-erythro-[³H]sphingosine (2 mCi/ml) for 24 h in Dulbecco's modified Eagle's medium at 37 °C. After incubation, the cells were removed with trypsin EDTA. The reaction was terminated by the centrifugation of the COS-1 cells, removal of the supernatant, and the addition of 2 ml of methanol. After transferring the samples to a glass tube, methanol and chloroform were added and the samples were sonicated and centrifuged for 30 min at 3000 x g. The supernatant was saved, and the pellets were reextracted with chloroform/methanol (2:1, v/v). The supernatants were combined with those of the first extraction, and 1 M NaCl was added. After centrifugation at 2000 x g, the lower layer was transferred to another tube and subjected to mild alkaline hydrolysis. The lipids were dried under nitrogen, dissolved in chloroform/methanol (2:1), applied to high performance TLC plates, and developed using the system described above. The corresponding spots for C1P were identified with a radiolabeled standard. Cells were labeled with D-erythro-[³H]sphingosine for 24 h. Following phagocytosis, the medium was changed with phosphate-buffered saline containing Ca²⁺ and Mg²⁺ and cells were challenged with erythrocytes (EIgG). The extraction was performed as outlined for phosphate labeling.

Lipid Raft Isolation—FcRIIA, FcRIIA/vector, and FcRIIA/hCERK-transfected COS-1 cells were challenged with opsonized EIgG and the EIgG not ingested were lysed. COS-1 cells were harvested by scraping into buffer containing 20 mM Tricine (pH 7.8), 0.25 M sucrose, and 1 mM EDTA. The cells were washed and then disrupted in the same buffer with 30 strokes in a Wheaton tissue grinder. The postnuclear supernatant was obtained by centrifugation of the cell lysates at 100 x g for 10 min. The plasma membrane fraction was removed from 30% Percoll 0.25 M sucrose buffer after centrifugation at 84,000 x g for 30 min. Caveolae membrane fractions were isolated from the purified plasma membrane fractions using Opti-Prep gradients as previously described (14). Aliquots of membrane fractions and the caveolae/lipid raft fractions were analyzed by SDS-PAGE. Proteins were transferred to a Polyvinylidene difluoride membrane and subjected to Western blotting using anti-caveolin-1, anti-c-Myc antibodies, and an antibody against hCERK.

Ceramide Assay—Lipids were extracted by the method of Van Veldhoven et al. (15). Total cellular ceramide was assayed by the method of Preiss et al. (16).

Antibody Generation and Immunoblotting—Human embryonic kidney 293 cells were transfected with vector or V5-CERK using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. Cells were lysed after 24 h in modified radioimmune precipitation assay buffer for 20 min at 4 °C. The cell lysates were centrifuged for 15 min at 15,000 x g at 4 °C. The supernatant proteins were separated on SDS-PAGE and transblotted to nitrocellulose. The blots were blocked with 5% nonfat dry milk for 1 h at room temperature followed by incubation with a polyclonal rabbit antiserum raised against a C-terminal hCERK peptide (RLFARGIEENPKPDSHS, 1:1000). After washing, the blots were incubated with a secondary antibody conjugated to horseradish peroxidase for 1 h at room temperature and immunopositive bands were visualized by chemiluminescence.

Treatment of COS-1 Cells with Methyl--cyclodextrin (mCD)—COS-1 cells were treated with mCD as described by Ottico et al. (17). The medium was discarded, and the dishes were washed three times with 1 ml of Locke's balanced saline solution (156 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO₃, 2.3 mM CaCl₂, 1 mM Mg Cl₂, 5.6 mM glucose, 5 mM HEPES (pH 7.4)) prewarmed at 37 °C. The cells were incubated with 2 ml of Locke's solution in the presence or absence of 5 mM mCD at 37 °C for 30 min.

Measurement of Membrane Fluidity—Excitation microscopy shows coexisting regions of different generalized polarization in red blood cells, in a renal tubular cell line, and in purified renal brush border labeled with a fluorescent probe, 2-dimethylamino-6-lauroylnaphthalene (Laurdan) (18). COS-1 cells, transfected with FcRIIA, FcRIIA/hCERK, FcRIIA/vector, and FcRIIA/G198DhCERK, were labeled with Laurdan. Following EIgG binding, microspectrophotometry was performed to assess local changes in membrane fluidity. As a control, regions of the Laurdan emission spectrum that are not sensitive to membrane fluidity were evaluated. The labeling of the COS-1 cells followed the methods of Parasassi et al. (18). Laurdan emission spectra were collected from specific regions of single cells using an imaging spectrophotometer system. Cells were labeled with 2.5 µM Laurdan for 25 min at room temperature and then washed at least three times with buffer. To increase light collection efficiency, the bottom port of the microscope was fiber-coupled optically to the input side of an Acton-150 (Acton Instruments, Acton, MA) imaging spectrophotometer. The exit side was connected to a liquid nitrogen-cooled intensifier attached to a Peltier-cooled I-MAX-512 camera (approximately -20 °C) (Princeton Instruments) (19, 20). The camera was controlled by a high-speed Princeton ST-133 interface and a Stanford Research Systems (Sunnyvale, CA) DG-535 delay gate generator. Microspectrophotometry used a 355-nm bandpass discriminating filter for excitation and a 405-nm long-pass dichroic mirror. Winspec software (Princeton Instruments) was used to analyze the data.

View larger version (56K): [in this window] [in a new window]   FIG. 1. The effect of hCERK transfection on the phagocytic index in COS-1 cells bearing FcRIIA. COS-1 cells were stably transfected with FcRIIA, FcRIIA/vector, FcRIIA/hCERK, and FcRIIA/G198DhCERK mutant and then challenged for 30 min with EIgG. A, photomicrographs at x400 comparing FcRIIA-transfected cells to cells transfected with FcRIIA/hCERK. B, the phagocytic indices measured as a function of time following EIgG treatment. Values represent the mean ± S.D. of four experiments, * and *** denote p < 0.05 and p < 0.001, respectively, and indicate the difference among FcRIIA, vector, G198DhCERK, and FcRIIA/hCERK-transfected cells compared with the 5-min time point. C, percent of cells ingesting EIgG. COS-1 cells were stably transfected with FcRIIA, FcRIIA/vector, FcRIIA/hCERK, and FcRIIA/G198DhCERK mutant and then challenged for 30 min with EIgG. Values represent the mean ± S.D. of four experiments. *** denotes p < 0.001.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

View larger version (12K): [in this window] [in a new window]   FIG. 2. Kinetics of ceramide kinase activity and ceramide formation in COS-1 cells. A, time course of ceramide kinase activity during phagocytosis in COS-1-transfected cells. COS-1 cells (3 x 106/dish) transfected with FcRIIA or FcRIIA/hCERK were challenged with EIgG (1 x 109/ml). At the indicated time points, COS-1 cells were removed with trypsin. The EIgG not internalized were removed by lysis, and the ceramide kinase activity was measured as described under "Experimental Procedures." The values represent the mean ± S.D. (n = 4). * denotes p < 0.05. B, the time course of ceramide generation during phagocytosis in COS-1 cells transfected with vector and FcRIIA/hCERK. COS-1 cells (3 x 106/dish) transfected with hCERK were challenged with EIgG (1 x 109/ml) at 37 °C. At the indicated time points, COS-1 cells were removed with trypsin. The EIgG not internalized were removed by lysis, and the ceramide generation was measured as described under "Experimental Procedures." The values represent the mean ± S.D. (n = 6 for CERK, and n = 3 for vector control).

Previous work has demonstrated the existence of phagocytosis-dependent ceramide formation in FcRIIA-transfected COS-1 cells (11). Ceramide mass was measured to determine whether the changes in ceramide kinase activity might secondarily lower ceramide levels in hCERK transfectants. There were no significant differences in ceramide levels between vector and CERK-transfected cells (Fig. 2B). Because ceramide levels were no lower in the hCERK transfectants, these data support the view that changes in C1P and not ceramide accounted for differences in phagocytic response.

View larger version (29K): [in this window] [in a new window]   FIG. 3. Generation of ceramide 1-phosphate from COS-1 cells bearing FcRIIA. A, the COS-1 stably transfected with either vector or hCERK were labeled with D-erythro-[3H]sphingosine (specific activity 20 Ci/mmol) for 24 h. The lipids were extracted as detailed under "Experimental Procedures." Basal changes in C1P labeling were observed in COS-1 cells bearing FcRIIA, vector, or hCERK labeled with the isotope. In COS-1 cells labeled with D-erythro-[3H]sphingosine, changes in C1P labeling were also measured following EIgG treatment for 30 min. B, C1P activity in D-erythro-[3H]sphingosine-labeled cells. C1P was measured before and after phagocytosis of EIgG at 30 min. The values represents the mean ± S.D. (n = 4). * denotes p < 0.001.

View larger version (15K): [in this window] [in a new window]   FIG. 4. Time course of ceramide 1-phosphate generation from COS-1 cells bearing FcRIIA/hCERK. Stably transfected COS-1 cells with hCERK were labeled with D-erythro-[3H]sphingosine (specific activity 20 Ci/mmol) for 24 h. The cell medium was changed with phosphate-buffered saline, and the cells were challenged with EIgG (1 x 109/ml) at 37 °C for different periods of time. The lipids were extracted as detailed under "Experimental Procedures." C1P was measured before and after phagocytosis at 7 and 30 min. The values represents the mean ± S.D. (n = 3). ** denotes p < 0.001.

View larger version (24K): [in this window] [in a new window]   FIG. 5. Caveolin-1 and hCERK expression in lipid rafts. Caveolin-1-containing membrane rafts and non-raft fractions were isolated as described under "Experimental Procedures." Samples were solubilized and immunoblotted. A, caveolin-1 expression in raft and non-raft fractions. B, c-Myc-hCERK expression in raft and non-raft fractions using an anti-c-Myc antibody. C, hCERK expression in raft and cytosol fractions during stimulation of hCERK-transfected cells with EIgG for 7, 20, and 30 min. D, ceramide kinase activity in raft and cytosol fractions. COS-1 cells (20 x 106/dish) transfected with FcRIIA/hCERK were challenged with EIgG (1 x 109/ml). At the indicated time points, COS-1 cells were removed with trypsin. The EIgG not internalized were removed by lysis, and cellular fractionation was performed as described under "Experimental Procedures." Ceramide kinase activity in raft and cytosol fractions during stimulation of hCERK-transfected cells with EIgG for 7, 20, and 30 min was measured as described under "Experimental Procedures" The values represent the mean ± S.D. (n = 4). * denotes p < 0.05; ** denotes p < 0.01.

Lipid rafts are believed to be small membrane microdomains containing cholesterol and sphingolipids (21). Due to the high degree of saturated fatty acyl content of these sphingolipids, lipids rafts are thought to form a distinct gel-like ordered lipid phase within cell membranes. These domains have been reported to contain a variety of signaling molecules.

Therefore, it was next confirmed that lipid rafts could be identified and isolated from COS-1 cells. Lipid rafts were subsequently identified by a caveolin-1 marker (Fig. 5A). Caveolin-1 was expressed in the lipid rafts but only weakly in non-membrane raft fractions obtained from FcRIIA, vector control, and hCERK-transfected cells. Utilizing an antibody to c-Myc, c-Myc-tagged hCERK was identified in the appropriate raft fraction generated from Myc-tagged hCERK vector but not from cells generated with the control vector. An anti-hCERK antibody was employed to evaluate the subcellular distribution of hCERK. Immunoblots yielded bands consistent with the known molecular weight of hCERK (Fig. 5C). Using this antibody, the intracellular localization of CERK during activation was evaluated. COS-1 cells transfected with hCERK were stimulated with EIgG for different periods of times and then subjected to fractionation. Immunoblots revealed that, under resting conditions, CERK was distributed within the cytosol and only weakly in the raft fraction. With stimulation, CERK was translocated to the raft fraction and diminished in the cytosolic fraction (Fig. 5C). The ceramide kinase activity was higher in the cytosolic fraction at the zero time point (11.23 ± 0.05 pmol/min/mg protein). As time progressed, the activity in the raft fraction increased from 4.95 ± 0.1 to 8.76 ± 0.07 pmol/min/mg protein at 7 min and to 14.86 ± 0.2 pmol/min/mg protein at 30 min following stimulation (Fig. 5D). Correspondingly, ceramide kinase activity was enriched in the caveolar fractions generated from non-stimulated transfected cells. The activity in hCERK-transfected cells was 4.9 ± 0.1 pmol/min/mg protein compared with 1.0 ± 0.08 pmol/min/mg protein for FcRIIA controls and 1 ± 0.04 pmol/min/mg protein from caveolae obtained from vector control-transfected cells.

View larger version (21K): [in this window] [in a new window]   FIG. 6. The effect of mCD treatment on phagocytic index. COS-1 cells following stable transfection with either vector or hCERK were labeled with D-erythro-[3H]sphingosine for 24 h. After metabolic labeling, the COS-1 cells were treated with mCD and then challenged for 30 min with EIgG. The phagocytic index over time was determined as described under "Experimental Procedures." Values represent the mean ± S.D. of three experiments. * denotes p < 0.05 and indicates the difference between FcRIIA- and FcRIIA/hCERK-transfected cells at the 30 min. ** denotes p < 0.01.

Having demonstrated that COS-1 cells possess lipid raft markers, a fluorescent probe was employed to determine whether these domains represent a distinct lipid environment. COS-1 cells were labeled with 2-dimethylamino-6-lauroylnaphthalene (Laurdan), a compound that is known to be embedded in the hydrophobic region of a phospholipid bilayer and to partition between crystalline and gel phases. Laurdan changes its steady-state emission spectrum when embedded in a fluid compared with gel phase membrane. Using high-sensitivity microspectrophotometry, emission spectra were collected from COS-1 cells undergoing phagocytosis both at the site of EIgG ingestion and at lateral cell body surfaces of the COS-1 cells away from the site of phagocytosis. Although no dramatic changes were noted at the sites of phagocytosis generated from COS-1 cells bearing FcRIIA, FcRIIA/vector or mutant G198DhCERK, the emission spectrum generated from FcRIIA/hCERK transfectants exhibited a dramatic shift in emission spectra of 37 nm (<0.001) at the site of phagocytosis (Fig. 7). However, no change in emission was noted at a lateral site distant from the point of contact with EIgG. These studies provide direct evidence in living COS-1 cells for the presence of L_o phase lipid domains in sites engaged in phagocytosis that spatially correspond to sites where lipid rafts are present.

View larger version (44K): [in this window] [in a new window]   FIG. 7. Lipid-ordered membrane domains in association with sites of phagocytosis in COS-1 cells expressing FcRIIA, FcRIIA/vector, FcRIIA/hCERK, and FcRIIA/G198DhCERK. COS-1 cells were labeled with Laurdan. Regions 1, 3, 5, and 7 (panels A, C, E, and G) correspond to membrane areas participating in phagocytosis, and the Laurdan emission spectra for these regions are denoted with the same numbers as shown below each micrograph. FcRIIA cells demonstrated a 0-nm shift (panel B), and the cells treated with FcRIIA/vector demonstrated a 3-nm shift (panel D). The FcRIIA/hCERK transfectants exhibited a shift in emission maximum of 37 nm (panel F), and FcRIIA/G198DhCERK-transfected cells (panel G) exhibited a shift in the emission of 2.2 + 0.6-nm shift (panel H). Quantitatively, the calculated general polarization of membrane regions 1, 2, 3, 6, and 7 were (-0.030), region 8 was (-0.024), region 4 was (-0.016), and membrane region 5 was (+0.088). 15 separate spectra were averaged together to generate the spectra shown in panels B, D, F, and H. The difference in both emission maximum and general polarization was highly significant.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
An emerging theme in the control of cellular signaling and metabolic regulation is the importance of the spatial localization of the molecules participating in cell activation. Recent advances in the study of cell membrane structure have led to the concept that microdomains exist within the fluid bilayer of the plasma membrane. One type of microdomain is the lipid raft, which is enriched with tightly packed sphingolipids and cholesterol (22). These rafts present in both excitable and non-excitable cells localize a number of proteins, including multiple signal transduction molecules, while excluding others (23). Different types of rafts are likely to exist based on the specific marker proteins and ultrastructure (24). Caveolae represent a well studied subpopulation of lipid rafts having an invaginated morphology and containing caveolin that interacts directly with several other proteins (23, 25, 26). Caveolin forms a scaffold onto which many classes of signaling molecules can assemble to generate signaling complexes. Signaling components that are highly enriched in caveolae include low molecular weight and heterotrimeric G proteins, src family kinases, mitogen-activated protein kinase, protein kinase C, and the p85 subunit of phosphatidylinositol 3-kinase (27, 28). The FcRIIA receptor also localizes to caveolae upon cross-linking (29). Ceramide generation from sphingomyelin may occur primarily in lipid rafts (30) and may facilitate the clustering of FcRIIA and its association with rafts (31). These observations suggest that caveolae may provide the structure for assembling critical components of the signaling pathways that mediate the early phagocytic response.

The recent cloning of hCERK has made it possible to evaluate the physiological functions of ceramide kinase and of C1P. Because polymorphonuclear leukocytes are not readily amenable to transfection, an in vitro cell culture system was chosen to study the mechanisms of C1P-induced phagocytosis. We took advantage of the ability of COS-1 cells to express a phagocytic phenotype when transfected with the FcRIIA. In the present study, COS-1 cells stably transfected with FcRIIA were also stably transfected with hCERK. Using this model, two important observations were made. First, the increased expression of hCERK resulted in heightened FcRIIA-mediated phagocytosis. In concert with the increase in phagocytosis, we observed that, in both FcRIIA- and FcRIIA/hCERK-transfected cells, ceramide kinase activity and C1P generation increased.

Second, in labeling cells with Laurdan, we observed that FcRIIA/hCERK transfectants exhibited a dramatic shift in emission during phagocytosis, corresponding to a distinct change in lipid-ordered structure. The change in Laurdan emission provides strong evidence for the existence of lipid raft like L_o domain in COS-1 cells at the site of phagosome formation. L_o phase lipids have been observed in reconstituted lipid rafts using Laurdan (32). Their demonstration in living cells has been limited to neutrophils. In this study, optical microspectrophotometry of Laurdan-labeled polarized neutrophils revealed the presence of large lipid raft-like domains at the lamellipodium (33).

View larger version (51K): [in this window] [in a new window]   FIG. 8. Kinetic study of lipid order membrane domains. Each spectrum was collected for 1 s with a 20-s period between each collection. A-C, spectra were collected from a region of the membrane distant from the site of phagocytosis denoted by the dark rectangle. D-F, spectra obtained from the vicinity of phagocytosis as denoted by the dark rectangles. Panels A and B show cells before and after the collection of the spectra in panel C, respectively. Similarly, panels D and E show cells before and after collection of the spectra shown in panel F. As time passes, the Laurdan spectra far from the site of phagocytosis do not change (panel C). However, the emission spectra at the site of phagocytosis change over time (panel F).

Cellular fractionation of COS-1 cell transfectants with hCERK also demonstrated that ceramide kinase activity is localized in cytosol and transferred to lipid rafts during stimulation with EIgG. Using an antibody raised against CERK, the cytosolic distribution of CERK was reported in mast cells (9). However, in another study, CERK was found in the membrane fraction in human embryonic kidney 293 cells (6). The observation of the translocation of CERK during activation in the present study may provide and explanation for these discrepant observations (30, 31).

Lipid rafts are also sites of signal transduction. Cross-linking of receptors may increase their affinity for rafts. Partitioning of receptors into rafts results in a new microenvironment where their phosphorylation state can be modified by local kinases and phosphatases modulating downstream signaling. The coalescence of several rafts may result in an amplification of a transduced signal.

One approach for studying the function of lipid rafts involves depleting cells of cholesterol. Lipid rafts are held together to a great extent via interactions between cholesterol and sphingolipids. COS-1 transfectants were treated with methyl--cyclodextrin, and phagocytosis decreased significantly. COS-1 transfectants were labeled with D-erythro-[³H]sphingosine and then treated with methyl--cyclodextrin. Treatment with methyl--cyclodextrin presumably disturbed the lipid-ordered structure of COS-1 transfectants and reduced phagocytosis.

Lipid and protein interactions play an important role in keeping the plasma membrane intact and functionally active. Many membrane-bound enzymes require a special conformation in order to display their optimal activity. There are a large number of lipids present with the potential to form rafts in the plasma membrane including C1P (35). Because of the presence of C1P, a liquid-order domain with higher rigidity than the surrounding plasma membrane was identified in FcRIIA/hCERK-transfected cells. This study supports the view that a regulated increase in C1P during phagocytosis may destabilize the membrane and lead to fusion.

	FOOTNOTES

 
^* This work is supported by National Institutes of Health Grants AI20065 (to L. A. B.) and DK055823 (to J. A. S,) and National Multiple Sclerosis Society grant (to H. R. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: 1150 W. Medical Center Dr., 1560 MSRB II, Ann Arbor, MI 48109-0676.

¹ The abbreviations used are: C1P, ceramide 1-phosphate; hCERK, human ceramide kinase; CERK, ceramide kinase; EIgG, erythrocytes; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; mCD, methyl--cyclodextrin.

	ACKNOWLEDGMENTS

 
We thank Dr. Roscoe Warner at the University of Michigan for assistance with the light microscopy experiments.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Bajjalieh, S. M., Martin, T. F., and Floor, E. (1989) J. Biol. Chem. 264, 14354-14360[Abstract/Free Full Text]
2. Martin, T. W. (1988) Biochim. Biophys. Acta 962, 282-296[Medline] [Order article via Infotrieve]
3. Kolesnick, R. N., and Hemer, M. R. (1990) J. Biol. Chem. 265, 18803-18808[Abstract/Free Full Text]
4. Shinghal, R., Scheller, R. H., and Bajjalieh, S. M. (1993) J. Neurochem. 61, 2279-2285[CrossRef][Medline] [Order article via Infotrieve]
5. Dressler, K. A., and Kolesnick, R. N. (1990) J. Biol. Chem. 265, 14917-14921[Abstract/Free Full Text]
6. Sugiura, M., Kono, K., Liu, H., Shimizugawa, T., Minekura, H., Spiegel, S., and Kohama, T. (2002) J. Biol. Chem. 277, 23294-23300[Abstract/Free Full Text]
7. Hinkovska-Galcheva, V. T., Boxer, L. A., Mansfield, P. J., Harsh, D., Blackwood, A., and Shayman, J. A. (1998) J. Biol. Chem. 273, 33203-33209[Abstract/Free Full Text]
8. Blackwood, R. A., Transue, A. T., Harsh, D. M., Brower, R. C., Zacharek, S. J., Smolen, J. E., and Hessler, R. J. (1996) J. Leukocyte Biol. 59, 663-670[Abstract]
9. Mitsutake, S., Kim, T. J., Inagaki, Y., Kato, M., Yamashita, T., and Igarashi, Y. (2004) J. Biol. Chem. 279, 17570-17577[Abstract/Free Full Text]
10. Pettus, B. J., Bielawska, A., Spiegel, S., Roddy, P., Hannun, Y. A., and Chalfant, C. E. (2003) J. Biol. Chem. 278, 38206-38213[Abstract/Free Full Text]
11. Hinkovska-Galcheva, V., Boxer, L., Mansfield, P. J., Schreiber, A. D., and Shayman, J. A. (2003) J. Biol. Chem. 278, 974-982[Abstract/Free Full Text]
12. Suchard, S. J., Hinkovska-Galcheva, V., Mansfield, P. J., Boxer, L. A., and Shayman, J. A. (1997) Blood 89, 2139-2147[Abstract/Free Full Text]
13. Hinkovska-Galcheva, V., Kjeldsen, L., Mansfield, P. J., Boxer, L. A., Shayman, J. A., and Suchard, S. J. (1998) Blood 91, 4761-4769[Abstract/Free Full Text]
14. Shu, L., Lee, L., Chang, Y., Holzman, L. B., Edwards, C. A., Shelden, E., and Shayman, J. A. (2000) Arch. Biochem. Biophys. 373, 83-90[CrossRef][Medline] [Order article via Infotrieve]
15. Van Veldhoven, P. P., Bishop, W. R., Yurivich, D. A., and Bell, R. M. (1995) Biochem. Mol. Biol. Int. 36, 21-30[Medline] [Order article via Infotrieve]
16. Preiss, J. E., Loomis, C. R., Bell, R. M., and Niedel, J. E. (1987) Methods Enzymol. 141, 294-300[Medline] [Order article via Infotrieve]
17. Ottico, E., Prinetti, A., Prioni, S., Giannotta, C., Basso, L., Chigorno, V., and Sonnino, S. (2003) J. Lipid Res. 44, 2142-2151[Abstract/Free Full Text]
18. Parasassi, T., Gratton, E., Yu, W. M., Wilson, P., and Levi, M. (1997) Biophys. J. 72, 2413-2429[Medline] [Order article via Infotrieve]
19. Kindzelskii, A. L., and Petty, H. R. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 9207-9212[Abstract/Free Full Text]
20. Worth, R. G., Kim, M. K., Kindzelskii, A. L., Petty, H. R., and Schreiber, A. D. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 4533-4538[Abstract/Free Full Text]
21. Simons, K., and Toomre, D. (2000) Nat. Rev. Mol. Cell. Biol. 1, 31-39[CrossRef][Medline] [Order article via Infotrieve]
22. Simons, K., and Ikonen, E. (1997) Nature 387, 569-572[CrossRef][Medline] [Order article via Infotrieve]
23. Harder, T., and Simons, K. (1997) Curr. Opin. Cell Biol. 9, 534-542[CrossRef][Medline] [Order article via Infotrieve]
24. Volonte, D., Galbiati, F., Li, S., Nishiyama, K., Okamoto, T., and Lisanti, M. P. (1999) J. Biol. Chem. 274, 12702-12709[Abstract/Free Full Text]
25. Okamoto, T., Schlegel, A., Scherer, P. E., and Lisanti, M. P. (1998) J. Biol. Chem. 273, 5419-5422[Free Full Text]
26. Hooper, N. M. (1999) Mol. Membr. Biol. 16, 145-156[CrossRef][Medline] [Order article via Infotrieve]
27. Oka, N., Yamamoto, M., Schwencke, C., Kawabe, J., Ebina, T., Ohno, S., Couet, J., Lisanti, M. P., and Ishikawa, Y. (1997) J. Biol. Chem. 272, 33416-33421[Abstract/Free Full Text]
28. Pike, L. J., and Casey, L. (1996) J. Biol. Chem. 271, 26453-26456[Abstract/Free Full Text]
29. Kwiatkowska, K., Frey, J., and Sobota, A. (2003) J. Cell Sci. 116, 537-550[Abstract/Free Full Text]
30. Liu, P., and Anderson, R. G. (1995) J. Biol. Chem. 270, 27179-27185[Abstract/Free Full Text]
31. Abdel Shakor, A. B., Kwiatkowska, K., and Sobota, A. (2004) J. Biol. Chem. 279, 36778-36787[Abstract/Free Full Text]
32. Dietrich, C., Bagatolli, L. A., Volovyk, Z. N., Thompson, N. L., Levi, M., Jacobson, K., and Gratton, E. (2001) Biophys. J. 80, 1417-1428[Medline] [Order article via Infotrieve]
33. Kindzelskii, A. L., Sitrin, R. G., and Petty, H. R. (2004) J. Immunol. 172, 4681-4685[Abstract/Free Full Text]
34. Papahadjopoulos, D., Vail, W. J., Newton, C., Nir, S., Jacobson, K., Poste, G., and Lazo, R. (1977) Biochim. Biophys. Acta 465, 579-598[Medline] [Order article via Infotrieve]
35. Mayor, S., and Maxfield, F. R. (1995) Mol. Biol. Cell 6, 929-944[Abstract]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				V. Hinkovska-Galcheva, A. Clark, S. VanWay, J.-B. Huang, M. Hiraoka, A. Abe, M. Borofsky, R. G. Kunkel, T. Shanley, J. A. Shayman, et al. Ceramide kinase promotes Ca2+ signaling near IgG-opsonized targets and enhances phagolysosomal fusion in COS-1 cells J. Lipid Res., March 1, 2008; 49(3): 531 - 542. [Abstract] [Full Text] [PDF]

				C. Graf, B. Zemann, P. Rovina, N. Urtz, A. Schanzer, R. Reuschel, D. Mechtcheriakova, M. Muller, E. Fischer, C. Reichel, et al. Neutropenia with Impaired Immune Response to Streptococcus pneumoniae in Ceramide Kinase-Deficient Mice J. Immunol., March 1, 2008; 180(5): 3457 - 3466. [Abstract] [Full Text] [PDF]

				N. F. Lamour, R. V. Stahelin, D. S. Wijesinghe, M. Maceyka, E. Wang, J. C. Allegood, A. H. Merrill Jr., W. Cho, and C. E. Chalfant Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis J. Lipid Res., June 1, 2007; 48(6): 1293 - 1304. [Abstract] [Full Text] [PDF]

				S. Spiegel and S. Milstien Functions of the Multifaceted Family of Sphingosine Kinases and Some Close Relatives J. Biol. Chem., January 26, 2007; 282(4): 2125 - 2129. [Full Text] [PDF]

				D. E. Modrak, D. V. Gold, and D. M. Goldenberg Sphingolipid targets in cancer therapy. Mol. Cancer Ther., February 1, 2006; 5(2): 200 - 208. [Abstract] [Full Text] [PDF]

				N. F. Lamour and C. E. Chalfant Ceramide-1-phosphate: The "missing" link in eicosanoid biosynthesis and inflammation Mol. Interv., December 1, 2005; 5(6): 358 - 367. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 280/28/26612    most recent M501359200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hinkovska-Galcheva, V. Articles by Shayman, J. A. Search for Related Content PubMed PubMed Citation Articles by Hinkovska-Galcheva, V. Articles by Shayman, J. A. Social Bookmarking                      What's this?